JP2014070075A5 - - Google Patents

Download PDF

Info

Publication number
JP2014070075A5
JP2014070075A5 JP2013228826A JP2013228826A JP2014070075A5 JP 2014070075 A5 JP2014070075 A5 JP 2014070075A5 JP 2013228826 A JP2013228826 A JP 2013228826A JP 2013228826 A JP2013228826 A JP 2013228826A JP 2014070075 A5 JP2014070075 A5 JP 2014070075A5
Authority
JP
Japan
Prior art keywords
dihydrobenzo
triazol
oxazepin
imidazo
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013228826A
Other languages
English (en)
Japanese (ja)
Other versions
JP5625101B2 (ja
JP2014070075A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014070075A publication Critical patent/JP2014070075A/ja
Publication of JP2014070075A5 publication Critical patent/JP2014070075A5/ja
Application granted granted Critical
Publication of JP5625101B2 publication Critical patent/JP5625101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013228826A 2009-09-28 2013-11-01 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法 Active JP5625101B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US61/246,381 2009-09-28
US33068510P 2010-05-03 2010-05-03
US61/330,685 2010-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012530282A Division JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2014070075A JP2014070075A (ja) 2014-04-21
JP2014070075A5 true JP2014070075A5 (enExample) 2014-08-07
JP5625101B2 JP5625101B2 (ja) 2014-11-12

Family

ID=43037239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Country Status (31)

Country Link
US (7) US8242104B2 (enExample)
EP (3) EP2845592A1 (enExample)
JP (2) JP5540101B2 (enExample)
KR (1) KR101428346B1 (enExample)
CN (2) CN104744491B (enExample)
AR (1) AR078187A1 (enExample)
AU (1) AU2010299816C1 (enExample)
BR (1) BR112012006807A2 (enExample)
CA (1) CA2772691C (enExample)
CL (1) CL2012000754A1 (enExample)
CO (1) CO6491026A2 (enExample)
CR (1) CR20120121A (enExample)
DK (1) DK2483278T3 (enExample)
EC (1) ECSP12011755A (enExample)
ES (2) ES2444779T3 (enExample)
HR (1) HRP20140229T1 (enExample)
IL (2) IL217558A (enExample)
MA (1) MA33531B1 (enExample)
MX (1) MX2012003591A (enExample)
MY (2) MY160064A (enExample)
NZ (1) NZ597833A (enExample)
PE (1) PE20121025A1 (enExample)
PL (1) PL2483278T3 (enExample)
PT (1) PT2483278E (enExample)
RS (1) RS53164B (enExample)
RU (2) RU2654068C1 (enExample)
SG (1) SG10201405049RA (enExample)
SI (1) SI2483278T1 (enExample)
TW (1) TWI423980B (enExample)
WO (1) WO2011036280A1 (enExample)
ZA (1) ZA201202199B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯pi3k抑制劑化合物及使用方法
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR20140032383A (ko) * 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
AR089999A1 (es) * 2012-02-17 2014-10-01 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos
CN104379163A (zh) * 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
AU2013299922B2 (en) * 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9266903B2 (en) * 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
TW201629026A (zh) 2015-02-02 2016-08-16 佛瑪治療公司 作為hdac抑制劑的3-烷基雙環[4,5,0]異羥肟酸
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
US10351576B2 (en) * 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
AU2016287189A1 (en) 2015-06-29 2017-10-12 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
JP6522807B2 (ja) * 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109982999A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 新的5-取代的咪唑基甲基衍生物
PL3851441T3 (pl) * 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
IL298518B2 (en) * 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
ES2947411T3 (es) * 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
BR112022008647A2 (pt) * 2019-11-04 2022-07-19 Betta Pharmaceuticals Co Ltd Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
CN113227101B (zh) * 2019-11-25 2024-10-11 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
CA3217763A1 (en) * 2021-05-03 2022-11-10 Bin Liu Tricyclic ubiquitin specific protease 1 inhibitor and use thereof
AU2022275275A1 (en) * 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
KR20240013791A (ko) 2021-05-28 2024-01-30 제넨테크, 인크. 벤족사제핀 옥사졸리디논 화합물을 제조하기 위한 공정
WO2024104435A1 (zh) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (zh) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 一种稠环化合物及其制备和应用
WO2025237374A1 (zh) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα抑制剂及其制备方法和医药用途
WO2026027658A1 (en) 2024-07-31 2026-02-05 Klostermeier Stefanie Phosphoinositide 3 kinase (pi3k) inhibitor for use in the treatment of neurological diseases
EP4686476A1 (en) 2024-07-31 2026-02-04 Klostermeier, Stefanie Phosphoinositide 3 kinase (pi3k) inhibitor for use in the treatment of neurological diseases
WO2026124464A1 (zh) * 2024-12-09 2026-06-18 微境生物医药科技(上海)有限公司 PI3Kα调节剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
EP0876375A1 (en) 1995-11-17 1998-11-11 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1355875A1 (en) 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
AU2003256650A1 (en) 2002-07-19 2004-02-09 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
MXPA05008400A (es) 2003-02-07 2005-10-05 Warner Lambert Co Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos.
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
MXPA06015275A (es) * 2004-07-01 2007-03-15 Merck & Co Inc Inhibidores de quinasa mitotica.
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
WO2008014483A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
AU2007281911B2 (en) 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
CL2007003879A1 (es) * 2006-12-29 2008-07-04 Basf Ag Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−3−キナーゼ(pi−3キナーゼ)阻害剤としてのテトラ−アザ−複素環
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯pi3k抑制劑化合物及使用方法
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use

Similar Documents

Publication Publication Date Title
RU2017114355A (ru) Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний
NZ597833A (en) Benzoxazepin pi3k inhibitor compounds and methods of use
JP2013529611A5 (enExample)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
JP2016501221A5 (enExample)
JP2013508382A5 (enExample)
HRP20150489T1 (hr) Imidazo[4,5-c]kinolini kao inhibitori dna-pk
MX2010001745A (es) Imidazoles fusionados para el tratamiento del cancer.
ME01462B (me) Vinilindazolilna jedinjenja"
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
JO3392B1 (ar) مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
JP2011517457A5 (enExample)
IL274936B2 (en) Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
JP2014513110A5 (enExample)
JP2017524668A5 (enExample)
JP2013510124A5 (enExample)
NZ601077A (en) Use of an adrenal hormone-modifying agent
JP2014513140A5 (enExample)
NZ586579A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2013502441A5 (enExample)
JP2017512803A5 (enExample)